Lilly (Eli) (LLY)

Lilly's price has climbed roughly 14% in the past month, its fastest pace in a while.

What is going on right now?

The stock has been rising quickly, and reports suggest that expectations around higher interest rates could put pressure on companies whose price is many times their earnings. Lilly's price is about 43 times what it earns per share right now.

How is the business itself doing?

Revenue grew nearly 48% and profits rose about 26%, driven mostly by its weight-loss and diabetes drugs: Zepbound, Mounjaro, Trulicity, and Jardiance. The company keeps roughly 33 cents of every dollar it brings in.

What stands out?

It generates about $11.1 billion in cash from operations and funds its own growth, which is unusual for a company expanding this fast.

What comes next?

Lilly's next earnings report is due October 29, the first to show how newer pricing discussions in the U.S. around its GLP-1 drugs are affecting actual sales.